Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with preserved ejection fraction via VEGF and sVEGFR-1
Turkish Journal of Biochemistry, cilt.44, sa.1, ss.25-31, 2019 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 1
- Basım Tarihi: 2019
- Doi Numarası: 10.1515/tjb-2018-0091
- Dergi Adı: Turkish Journal of Biochemistry
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.25-31
- Anahtar Kelimeler: Heart failure, VEGF, sVEGFR-1
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: In this study, our aim was to investigate the clinical significance of VEGF, sVEGFR-1 in HFpEF patients. Materials and methods: Seventy-two participants enrolled in this cross-sectional case-control study including HFpEF patients (n = 41) and healthy (n = 31) subjects. Blood samples were collected and serum VEGF, sVEGFR-1 analysis, and transthoracic echocardiography were performed. Results and discussion: The average sVEGFR-1 level of HFpEF patient group was significantly higher than the control group (respectively 0.136 ng/L (0.04–0.34), 0.06 ng/L (0.01–0.25); p < 0.001). The average VEGF level of HFpEF patients using beta blocker was significantly higher than the HFpEF patients not using it (respectively 0.585 ± 0.194 ng/L; 0.349 ± 0.269 ng/L; p = 0.025). The average VEGF level of HFpEF patients using statins was significantly higher than the HFpEF patients without a medication (respectively 0.607 ± 0.099 ng/L; 0.359 ± 0.273 ng/L; p = 0.038). Conclusion: Our study is the first study demonstrating the relations among HFpEF, accompanying morbidities, VEGF and sVEGFR-1 levels. Statins and beta blockers may have positive effects on angiogenesis in HFrEF patients via increasing VEGF levels.